Remarkable bone formation following gefitinib for extensive lytic bone metastasis: A report of two cases
Document Type
Article
Publication Date
1-1-2016
Abstract
Gefitinib inhibits the epidermal growth factor receptor tyrosine kinase and improves survival in patients with non-small-cell lung cancer. We report 2 patients with extensive lytic bony metastasis in the spine and pelvis secondary to advanced pulmonary adenocarcinoma who were treated with gefitinib and had remarkable bone formation in the lytic bone lesions in the spine and pelvis. Surgery for stabilisation was avoided.
Keywords
Adenocarcinoma of lung, Bone cysts, Gefitinib, Neoplasm metastasis, Receptor, Epidermal growth factor
Divisions
fac_med
Publication Title
Journal of Orthopaedic Surgery
Volume
24
Issue
3
Publisher
Hong Kong University Press
COinS